SG11201702129XA - Veliparib in combination with carboplatin and paclitaxel for the treatment of non-small cell lung cancer in smokers - Google Patents

Veliparib in combination with carboplatin and paclitaxel for the treatment of non-small cell lung cancer in smokers

Info

Publication number
SG11201702129XA
SG11201702129XA SG11201702129XA SG11201702129XA SG11201702129XA SG 11201702129X A SG11201702129X A SG 11201702129XA SG 11201702129X A SG11201702129X A SG 11201702129XA SG 11201702129X A SG11201702129X A SG 11201702129XA SG 11201702129X A SG11201702129X A SG 11201702129XA
Authority
SG
Singapore
Prior art keywords
veliparib
smokers
carboplatin
paclitaxel
treatment
Prior art date
Application number
SG11201702129XA
Other languages
English (en)
Inventor
Vincent Giranda
Gary Gordon
Mark D Mckee
Jane Qian
Qin Qin
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of SG11201702129XA publication Critical patent/SG11201702129XA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11201702129XA 2014-09-16 2015-09-16 Veliparib in combination with carboplatin and paclitaxel for the treatment of non-small cell lung cancer in smokers SG11201702129XA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462051040P 2014-09-16 2014-09-16
PCT/US2015/050367 WO2016044384A1 (en) 2014-09-16 2015-09-16 Veliparib in combination with carboplatin and paclitaxel for the treatment of non-small cell lung cancer in smokers

Publications (1)

Publication Number Publication Date
SG11201702129XA true SG11201702129XA (en) 2017-04-27

Family

ID=54207780

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201702129XA SG11201702129XA (en) 2014-09-16 2015-09-16 Veliparib in combination with carboplatin and paclitaxel for the treatment of non-small cell lung cancer in smokers

Country Status (15)

Country Link
US (2) US9623009B2 (es)
EP (1) EP3193861A1 (es)
JP (1) JP2017527627A (es)
KR (1) KR20170055536A (es)
CN (1) CN107073015B (es)
AU (1) AU2015317856B2 (es)
CA (1) CA2959175A1 (es)
CL (1) CL2017000636A1 (es)
DO (1) DOP2017000069A (es)
IL (1) IL250708A0 (es)
MX (1) MX2017003304A (es)
PH (1) PH12017500505A1 (es)
RU (1) RU2017112960A (es)
SG (1) SG11201702129XA (es)
WO (1) WO2016044384A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7033601B2 (ja) * 2017-01-05 2022-03-10 コリア リサーチ インスティチュート オブ バイオサイエンス アンド バイオテクノロジー 抗コチニンキメラ抗原受容体を発現するナチュラルキラー細胞
WO2018187485A1 (en) * 2017-04-04 2018-10-11 The George Washington University Combination therapy for treating cancer
US20200129482A1 (en) * 2017-06-26 2020-04-30 Abbvie Inc. Treatment of non-small cell lung cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080146638A1 (en) * 2006-01-17 2008-06-19 Abbott Laboratories Combination therapy with parp inhibitors
EP2059802A4 (en) * 2006-09-05 2010-09-08 Bipar Sciences Inc METHODS FOR DESIGNING PARP INHIBITORS AND USES THEREOF
EP2440203A4 (en) * 2009-06-04 2017-06-07 The Governors of the University of Alberta Small molecule inhibitors of polynucleotide kinase/phosphatase. poly(adp-ribose) polymerase and uses thereof
RU2014150506A (ru) * 2012-05-15 2016-07-10 Эббви Инк. Велипариб в комбинации с лучевой терапией всего мозга для лечения метастазов в головной мозг
JP6324381B2 (ja) * 2012-07-31 2018-05-16 クラウン バイオサイエンス インコーポレイテッド（タイカン） 抗ｅｇｆｒ薬物による処置のための非小細胞肺癌患者を同定するための組織学的マーカー
US20140187537A1 (en) * 2013-01-03 2014-07-03 Emory University Methods of predicting outcomes of chemotherapy treatments and alternative therapies

Also Published As

Publication number Publication date
CA2959175A1 (en) 2016-03-24
CL2017000636A1 (es) 2017-11-03
US20170172985A1 (en) 2017-06-22
US9623009B2 (en) 2017-04-18
EP3193861A1 (en) 2017-07-26
KR20170055536A (ko) 2017-05-19
AU2015317856B2 (en) 2020-05-14
US20160074368A1 (en) 2016-03-17
PH12017500505A1 (en) 2017-08-30
JP2017527627A (ja) 2017-09-21
CN107073015B (zh) 2020-07-21
DOP2017000069A (es) 2017-05-15
MX2017003304A (es) 2017-08-15
RU2017112960A (ru) 2018-10-17
AU2015317856A1 (en) 2017-03-16
IL250708A0 (en) 2017-04-30
WO2016044384A1 (en) 2016-03-24
CN107073015A (zh) 2017-08-18

Similar Documents

Publication Publication Date Title
HK1249524A1 (zh) 用於治療血載癌症的免疫檢查點抑制劑
HK1256283A1 (zh) 治療癌症有用的二氫咪唑並吡嗪酮衍生物
HK1212248A1 (en) Inhibitors of met, vegfr and ret for use in the treatment of lung adenocarcinoma metvegfr ret
IL276733A (en) Use of Aribolin in cancer treatment
HRP20181490T1 (hr) Spojevi 1, 3, 4-tiadiazola i njihova upotreba u liječenju raka
HK1252370A1 (zh) 用於治療非小細胞肺癌的治療方法和組合物
IL262656A (en) Nanoliposomal irinotecan for use in the treatment of small cell lung cancer
IL251903B (en) Epilimod for use in the treatment of colon cancer
IL290251A (en) Combination for effective treatment of metastatic cancer in patients
IL250708A0 (en) Veliparib in combination with carboplatin and paclitaxel for the treatment of non-small cell lung cancer in smokers
IL259358A (en) Bis-pyridazine compounds and their use in treating cancer
IL246065A0 (en) Valiprib in combination with carboplatin for the treatment of triple negative breast cancer
GB201514015D0 (en) Novel pyridazinones and their use in the treatment of cancer
GB201510764D0 (en) bis-Pyridazine compounds and their use in treating cancer
GB201411111D0 (en) bis-Pyridazine compounds and their use in treating cancer
GB201403086D0 (en) Selection of virus and agent useful in the treatment of cancer